



Diagnostic and Therapeutic Challenges in Primary CNS Lymphoma

Tracy Batchelor, M.D.
Brigham and Women's Hospital
Harvard Medical School

Disclosures

(07/15/20-07/15/21)

- Up To Date, Inc
- Audiodigest
- Oakstone

Learning Objectives

- To understand the clinical presentation, diagnosis, and initial evaluation of patients with PCNSL
- To understand the basic induction and consolidation treatment options and outcomes for newly diagnosed PCNSL patients
- To understand novel treatment options in clinical trials for refractory or relapsed PCNSL

Key Messages

- PCNSL is a rare type of brain cancer with unique biological, clinical, and radiographic features
- There are effective treatments for PCNSL and many patients will enter remission
- The goals of treatment are to achieve cure and to avoid disabling neurotoxicity
- There are several different options for induction and consolidation treatment in newly diagnosed PCNSL
- Many patients will either have refractory disease or will relapse and will require additional treatment
- Novel therapies are needed

References

- CBTRUS (2019). CBTRUS Statistical Report. www.cbtrus.org
- Batchelor TT, DeAngelis LM (Ed). Lymphoma and Leukemia of the Nervous System, 2nd ed. New York: Springer; 2013
- Grommes C, et al, Neuro Oncol 21: 296-305, 2019
- Abrey L, et al, J Clin Oncol 23: 5034-5043, 2005
- Barajas RF, et al, Neuro Oncol 23: 1056-1071, 2021
- Correa D, et al. Ann Oncol 18: 1145-1151, 2007
- Ferreri AJ, et al Lancet Haematol 2017
- Soussain, et al Eur J Cancer, 117: 121-130, 2019
- Ghesquieres H, et al, Ann Oncol 30: 621-628, 2019
- Frigault M, et al Blood, 134: 860-866, 2019